LabGenomics "Service Contract with IMD, OCPMG... Strengthening Cancer Diagnosis Competitiveness in the US"

LabGenomics announced on the 9th that its CliaLab IMD has signed a service level agreement (SLA) with Orange County Pathology Medical Group (OCPMG) and established a collaborative partnership.

OCPMG is a large pathology group that has collaborated with various institutions in Orange County, Southern California, USA, for about 50 years. It has established partnerships with St. Joseph’s Providence, Heritage Medical Group, and Children’s Hospital of Orange County (CHOC), and specializes in various subfields such as gastroenterology, urology, and dermatology.

IMD, acquired by LabGenomics’ US subsidiary last October, operates three CliaLabs located in Sacramento, Aurora, and Berkeley in the western and central regions of the United States. It has been producing results by enhancing expertise and efficiency in cancer diagnosis based on pathology and molecular testing, and by building a business model that collaborates with oncology and pathology groups across the US.

Through this contract, IMD will conduct technical analysis (TC) of flow cytometry and fluorescence in situ hybridization (FISH) pathology tests for dermatopathology (DermPath). In particular, it will provide both technical analysis (TC) and pathologist analysis (PC) for FISH tests analyzing epithelial growth factor receptor 2 (Her2) and receptor protein (Neu), which are most commonly performed for breast and gastric cancer patients. The company explained that by comparing slide samples with images obtained using digital pathology scanners during TC, clinical data for commercializing digital pathology technology can be secured. This clinical data acquisition is expected to enable testing and advancement of digital pathology scanner technology, allowing for rapid market launch.

A representative from LabGenomics’ Global Business Division stated, “This contract is the first achievement since acquiring IMD and will further expand our influence in the Southern California region where OCPMG is located. We plan to expand services with various pathology and cancer tests.” They added, “By utilizing IMD’s self-developed Laboratory Information Management System (LIMS), integrated management from specimen collection to analysis and result delivery is possible, enabling efficient and rapid provision of high-quality services.”

Luis Zumbas, Chief Operating Officer (COO) of IMD, said, “The strategic collaboration between the two companies will be an important opportunity to expand customer services. We are discussing expanding the partnership to include various pathology tests and cancer tests such as urology and gastroenterology.” He added, “We will continuously seek additional business development opportunities to further solidify LabGenomics’ position in the US diagnostics market.”

This content was produced with the assistance of AI translation services.